Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport.
about
Enhancement of blood-tumor barrier permeability by Sar-[D-Phe8]des-Arg9BK, a metabolically resistant bradykinin B1 agonist, in a rat C6 glioma modelAdenosine receptor signaling: a key to opening the blood-brain doorNanoscale drug delivery systems and the blood-brain barrierInduction of selective blood-tumor barrier permeability and macromolecular transport by a biostable kinin B1 receptor agonist in a glioma rat modelBlood brain barrier: a challenge for effectual therapy of brain tumorsRhythmic expression of adenylyl cyclase VI contributes to the differential regulation of serotonin N-acetyltransferase by bradykinin in rat pineal glandsStrategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models.Quantitative evaluation of monocyte transmigration into the brain following chemical opening of the blood-brain barrier in miceMannitol-enhanced delivery of stem cells and their growth factors across the blood-brain barrier.Advances in strategies to improve drug delivery to brain tumors.Adenosine receptor signaling modulates permeability of the blood-brain barrier.Peptide gH625 enters into neuron and astrocyte cell lines and crosses the blood-brain barrier in ratsTransplantation of human umbilical cord blood cells in the repair of CNS diseases.Vascular aspects of neuroprotection.Biomedical Technologies for in vitro Screening and Controlled Delivery of Neuroactive Compounds.Selective permeabilization of the blood-brain barrier at sites of metastasis.Gene therapy in Alzheimer's disease - potential for disease modificationExperimental methods and transport models for drug delivery across the blood-brain barrier.Novel and emerging strategies in drug delivery for overcoming the blood-brain barrier.Liposomes and nanotechnology in drug development: focus on neurological targets.Which drug or drug delivery system can change clinical practice for brain tumor therapy?In vitro and in vivo characterization of several functionalized ultrasmall particles of iron oxide, vectorized against amyloid plaques and potentially able to cross the blood-brain barrier: toward earlier diagnosis of Alzheimer's disease by moleculaRecent prospective of surface engineered Nanoparticles in the management of Neurodegenerative disorders.Primary Role for Kinin B1 and B2 Receptors in Glioma Proliferation.Kallikrein-kinin system as the dominant mechanism to counteract hyperactive renin-angiotensin system.Bradykinin increases resensitization of purinergic receptor signaling in glioma cells.Neuroprotective effects of encapsulated CNTF-producing cells in a rodent model of Huntington's disease are dependent on the proximity of the implant to the lesioned striatum.Monitoring proteins using in vivo near-infrared time-domain optical imaging after 2-O-hexyldiglycerol-mediated transfer to the brain.Intracerebral xenotransplantation of GFP mouse bone marrow stromal cells in intact and stroke rat brain: graft survival and immunologic response.The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma.Blood-brain barrier dysfunction and recovery after ischemic stroke.The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study.QbD approach to investigate product and process variabilities for brain targeting liposomes.Mechanisms involved in kinin-induced glioma cells proliferation: the role of ERK1/2 and PI3K/Akt pathways.Impact of Bradykinin Generation During Thrombolysis in Ischemic StrokeGlioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier
P2860
Q24803562-167D71D7-3851-4D45-8899-CB644B9E6434Q26795435-9DBDB412-C463-4CE8-B967-D461297D2B4BQ27026978-9994AC90-6667-4FA5-B43D-E4553612D10EQ27302402-71E5EF51-6C97-4D24-AB8C-7FC4C9203E96Q28081947-D3B36357-38F0-4385-A3A4-281EEE0F3471Q28571904-18D40BFD-D371-4DF0-8DDD-A02A6098DD2DQ30366921-C63D2E65-9D41-47B6-93EB-E3FC9206FA7BQ33484368-D502BE6F-1346-4D27-903A-37998641D697Q33697504-52BD03E6-26AE-4399-A994-6699629790E5Q33852356-2515AE6C-B67C-4989-A44E-EB8B91B0D9FDQ34000631-B26C2B71-47F5-434C-A084-1C05B86354D1Q34216355-211EEFD1-CF5D-46C1-B03D-C29A30C1B159Q35189757-80550E4C-DD63-4EB0-8841-78578F40CDCAQ35681487-3B0C7302-5C4E-499A-84B4-FD8646FA7434Q36052719-ECC9FADA-6720-4A7C-AB43-0CCDACFA0FA2Q37010459-513CFD03-A0FF-48F6-B0DB-2A2DC06C5717Q37281601-0C42EA9F-FF86-477B-B055-5F0E3CEA5CB3Q37295252-9B27162E-FA3F-49FA-8858-FC415FBB4FCBQ37698934-265799A4-EDEF-44B0-9788-29943E56D8A0Q37855817-64D3BE7B-D4C4-4E15-A6C8-31A6314C8B69Q38088959-ADF5287A-4A33-40A3-B1CA-5130C6346345Q38090394-CAF4E885-4102-4597-AF2B-3A1C95233574Q38447377-E8DF418C-4065-4FDA-9654-EC2B1C33FB60Q38536735-CF221831-8056-4521-B3BF-05C6839E8116Q39184741-19C13FD9-B036-459F-8B55-16F791036B80Q39224534-10F9D41E-D05F-41F5-A694-D06304EB19ACQ39651000-743A8325-2C88-476B-9942-38CBB2067939Q40546909-ABDBC256-1DA6-4974-8236-3FE3E1FA85C9Q42661918-403A4EEA-1DA3-4390-AEBA-0592A1676FD2Q44931896-D63EB3F8-C687-41A2-B873-D0172F7C1D15Q47864998-179E679B-02E7-499C-ACC8-9AEB6CBD206AQ47910464-C1309512-40D2-4527-B103-1B830BAA57EBQ48258159-FF2898DB-240F-4153-90C4-774EACD26639Q48488102-B4C7AC2A-F4D9-4DB7-A121-1B85CD779FC0Q48640997-C6632287-96A8-4803-AFB4-D6D9708AA869Q58179635-5F5EB650-9AFD-46CD-99D4-FD1CF97A61FAQ59134092-05173BEC-4FF9-4BC6-9216-3AFBFD0B10EC
P2860
Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Facilitation of drug entry int ...... in receptor agonist, Cereport.
@ast
Facilitation of drug entry int ...... in receptor agonist, Cereport.
@en
type
label
Facilitation of drug entry int ...... in receptor agonist, Cereport.
@ast
Facilitation of drug entry int ...... in receptor agonist, Cereport.
@en
prefLabel
Facilitation of drug entry int ...... in receptor agonist, Cereport.
@ast
Facilitation of drug entry int ...... in receptor agonist, Cereport.
@en
P1476
Facilitation of drug entry int ...... nin receptor agonist, Cereport
@en
P2093
D F Emerich
P304
P356
10.1016/S0361-9230(03)00043-1
P577
2003-05-01T00:00:00Z